Corazon (Corsee) D. Sanders sold $896k of ONC
director at BeOne Medicines Ltd.. 2,627 shares at an average of $340.90, traded Nov 26, 2025, filed Dec 1, 2025.
Score components
- +15RoleDirector
- +24Trade size$896k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- +10Role exitThe filing reports the insider leaving
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001796536-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 26, 2025 | MOption exercise American Depositary Shares | +2,627 | $159.03 | $418k | 2,627 | Dec 1, 2025 |
| Nov 26, 2025 | SOpen-market sale American Depositary Shares | -1,823 | $340.20 | $620k | 804 | Dec 1, 2025 |
| Nov 26, 2025 | SOpen-market sale American Depositary Shares | -804 | $342.47 | $275k | 0 | Dec 1, 2025 |
| Nov 26, 2025 | MOption exercise Share Option (Right to Buy)derivative | -34,151 | $0.00 | $0 | 0 | Dec 1, 2025 |
Related signals
Other insiders at BeOne Medicines Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $418k 1,115 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $11M 31,028 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $13M 38,287 shares | -527% | |
| 49Moderate | BeOne Medicines Ltd. | Titus B. Ball Principal Accounting Officer | $47k 132 shares | -100% | |
| 58Moderate | BeOne Medicines Ltd. | John Oyler Chief Executive Officer | $31M 100,000 shares | -100% | |
| 27Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $214k 664 shares | -200% | |
| 80Strong | BeOne Medicines Ltd. | Xiaobin Wu President and COO | $1.5M 3,991 shares | -100% | |
| 80Strong | BeOne Medicines Ltd. | Xiaobin Wu President and COO | $5.8M 16,009 shares | -100% | |
| 30Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $348k 996 shares | -100% | |
| 25Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $3.7M 10,671 shares | -960% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.